Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease
about
Erdheim-Chester Disease: a comprehensive review of the literatureElotuzumab: the first approved monoclonal antibody for multiple myeloma treatmentTreating rheumatological diseases and co-morbidities with interleukin-1 blocking therapiesInterleukin-1 loop model for pathogenesis of Langerhans cell histiocytosisConsensus guidelines for the diagnosis and clinical management of Erdheim-Chester diseaseErdheim–Chester DiseaseMir-155 is overexpressed in systemic sclerosis fibroblasts and is required for NLRP3 inflammasome-mediated collagen synthesis during fibrosis.Clinical considerations and key issues in the management of patients with Erdheim-Chester Disease: a seven case series.An expanding role for interleukin-1 blockade from gout to cancer.Erdheim-Chester disease: from palliative care to targeted treatment.Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report.A tale of two histiocytic disordersTreating inflammation by blocking interleukin-1 in humans.Oncogene-induced senescence as a new mechanism of disease: the paradigm of erdheim-chester disease.The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm.Efficacy and safety of elotuzumab for the treatment of multiple myeloma.Interleukin-1 Blockade: An Update on Emerging Indications.Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim-Chester disease.BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease.Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults.Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester diseaseElotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.Improvement of Erdheim-Chester disease-related renal failure after treatment with anakinra.Efficacy of biological agents in the treatment of Erdheim-Chester disease.CNS Erdheim-Chester Disease: A Challenge to Diagnose.A compound chimeric antigen receptor strategy for targeting multiple myeloma.Rapid progression to cardiac tamponade in Erdheim-Chester disease despite treatment with interferon alpha.Multiple cutaneous, oropharyngeal and pulmonary nodules.Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in Erdheim-Chester disease: Towards the paradigm of combined targeting and immune therapies.A Rare Case of Erdheim-Chester Disease (Non-Langerhans Cell Histiocytosis) with Concurrent Langerhans Cell Histiocytosis: A Diagnostic and Therapeutic Challenge.The clinical spectrum of Erdheim-Chester disease: an observational cohort studyAnakinra Therapy for Non-cancer Inflammatory DiseasesCombination of adalimumab with lower dose of methylprednisolone in Erdheim-Chester disease with systemic involvement
P2860
Q21202851-F78768C7-5D26-4357-B178-F69FF001CAC1Q26738944-A25C26E9-E12A-4163-B79B-39084A3826DBQ26799747-CC75EF7D-B486-49CC-8DF7-B69DDEE43A0CQ28083455-A00DF6E3-A74E-4450-AB1D-11067474DBD5Q28240576-F797A03B-D422-4733-90EE-5BA9C39F2441Q30047444-D3DA88E0-409E-4BA3-964E-A765800D39E7Q33808382-06C78DAF-E44A-4474-8F6F-8BE1566975B3Q34591365-07D6C567-0BF2-4807-8565-956DCBF487F5Q35219001-1F13E1FF-DC64-4BE6-A00E-73287C22080CQ35227699-6095C9AC-DCD3-490F-834E-411801D5D4FFQ35618455-E563E560-85DC-4DC7-8FBF-695E1D0F1DD9Q36565617-AEAD91DE-339C-4A92-BCC9-96C103772BB0Q37636664-8E77532D-E833-443A-B595-1AB523D01C15Q38225118-DABF238A-C1A8-4191-8145-09D5D631F8FDQ38551516-221BB206-1562-422F-9704-7610BDFC9E7EQ39070515-59B654D7-6A18-4546-B52B-83BB95CDDC6AQ39301613-DA76CDC1-6D47-46D2-8DFB-398D286ACC40Q39397373-6E67B085-0E12-4C04-BB4F-4EB3DA2AE56FQ40180256-E3F092F5-F181-43BC-8D3B-8DAD6B6F8AB9Q40229747-08958EBA-290E-4D5E-821A-73F4DBC71EFFQ40921309-ABFC493A-1676-4BE7-BE01-8C555156E86FQ42386218-23FAC70D-61D6-4CA0-AA0E-343CC177CD69Q42794690-8043E16B-3D40-4490-B4C5-F554DBF0072FQ43086913-B16EA311-6F08-4674-93AC-188D4307E3D5Q47589462-83F09599-4BAA-4FD5-8B68-234B3C4EC167Q47592137-C2075602-27C0-4FD0-977D-5B8A3E52E2BBQ48649390-84F4481D-478A-4D6D-AF0D-C3619DB03455Q53068572-CA0F7B1D-5753-4762-A969-76F0F63BAB6EQ53629796-0D958B9B-DA8D-4D35-AE68-5CAD0C998928Q54203888-F48C92CB-044B-4B9E-9322-0F525F35A0BDQ55274222-E9BF48B6-307D-4AFC-A06E-5E346B825EBAQ57453129-33BF839F-61CB-4C11-915E-4217BBE0CD19Q59136398-DFBA2884-E9F2-4F60-9901-FB5E22C8E0C8Q59279866-09366E49-4A9B-49AA-82D0-08BB257D8242
P2860
Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease
@ast
Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease
@en
Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease
@nl
type
label
Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease
@ast
Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease
@en
Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease
@nl
prefLabel
Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease
@ast
Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease
@en
Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease
@nl
P2093
P50
P1433
P1476
Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease
@en
P2093
Achille Aouba
Boris Bienvenu
Christian Pagnoux
Frederique Larousserie
Henri Bensadoun
Loïc Guillevin
Mathilde de Menthon
Nicolas Martin Silva
Nicole Provost
Sophie Candon
P304
P356
10.1182/BLOOD-2010-04-279240
P407
P577
2010-08-19T00:00:00Z